Clinical trial · Interventional
Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer
A Phase II Study of Induction Chemotherapy Followed by Surgical Treatment in Locally Advanced Oropharyngeal And Supraglotic Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to assess the efficacy of induction chemotherapy followed by transoral surgical treatment and neck dissection, in definitive management of moderately advanced oropharyngeal squamous cell carcinoma. The surgical treatment will carry out Transoral Robotic Surgery (TORS) or Transoral Laser Microsurgery (TLM) for the primary tumor, and neck dissection for the management of cervical lymph nodes. The primary outcome measure will be disease specific survival (DSS). The secondary oncologic outcome measures will be locoregional control, relapse free survival, overall survival, and Quality of Life (QOL).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Cisplatinum | Drug | Cisplatin | ALIAS |
| Docetaxel | Drug | Docetaxel | ALIAS |
| Transoral Robotic Assisted Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Induction Therapy with 3 cycles
- description
- Cisplatin 75mg/m2 IV and Taxotere 75mg/m2 every 3 weeks for 3 cycles (Induction Chemotherapy) followed by surgical treatment
- interventionNames
- Drug: Cisplatinum
- Drug: Docetaxel
- Drug: Carboplatin
- Procedure: Transoral Robotic Assisted Surgery
Primary outcomes (1)
- measure
- Disease specific survival (DSS)
- timeFrame
- 3 years
- description
- this parameter is a number will tell the chances of staying free of the head and neck cancer after the study treatment.
Secondary outcomes (4)
- measure
- Relapse-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy proven squamous cell carcinoma of the oropharynx (tonsil, base of tongue, vallecula, soft palate) and supraglottis. * Stages III (T1N1, T2N1, T3N0, T3N1) and stage IVA (T1N2, T2N2, T3N2, very select earlyT4) disease not previously treated with any method (Surgery, Radiation or Chemotherapy) * No evidence of distant metastatic disease * Fit for surgery and primary tumor assessed surgically resectable (by surgical PI) via transoral approach * Age \> 18 years * Karnofsky performance status \> 60%, or ECOG \< 2 * ANC \> 2,000, platelets \> 100,000 and calculated creatinine clearance \>50 cc/min * Signed study specific consent form * Protocol begins within 4 weeks of biopsy and within 3 weeks of the latest medical imaging. * No other malignancies except cutaneous basal or squamous cell cancer within the last 5 years * Patients must have measurable disease based on RECIST. * Men and women of child bearing potential must agree to use effective contraception while on the study, and women must have a negative pregnancy test, and not be lactating. Exclusion Criteria: * Patients with advanced T4 cancer judged unresectable by transoral approach by surgical PI. * Patients with N3 disease (Stage IVB). * Patients with distant metastatic disease (Stage IVC). * Patients with radiologically positive neck nodes with radiological evidence of extracapsular nodal tumor invasion. * Patients having anatomy not allowing transoral access and exposure for surgery(Judged by the surgical PI at the time of biopsy under general anesthesia) * Patients with prior head and neck cancer at any time (other than basal or squamous cell cancer of the skin) * Coexistent second malignancy or history within 5 years of prior malignancy (other than basal or squamous cell cancer of the skin or curatively treated Stage I carcinoma of the cervix) renders the patient ineligible. * Patients with peripheral neuropathy \>/= grade 1 will not be eligible for the study. * Patients who have had prior Taxanes or Cisplatin * Patients with concurrent infection are not eligible. All patients must be afebrile for at least 3 days prior to start of therapy unless fever is due to tumor. * Patients with coexisting medical illness of a severity that might interfere with treatment or follow-up, or who do not have the ability to give informed consent. * Patients who have received prior radiation therapy, surgery and chemotherapy for the tumor being treated. * Patients must not be receiving any other investigational agent while on the study.
References
Publications (0)
Data not yet available